Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity.
Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, Gallant CW, Christmas R, Gao JR, James MJ, Abin-Fuentes A, Momin M, Bergeron C, Fisher A, Miller PF, West KA, Lora JM. · 2020
Read Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. by Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, Gallant CW, Christmas R, Gao JR, James MJ, Abin-Fuentes A, Momin M, Bergeron C, Fisher A, Miller PF, West KA, Lora JM. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7264239.txt.
Description
Leventhal and co-authors engineer a harmless gut bacterium into a living cancer medicine. Their study appeared in Nature Communications. The strain, called SYNB1891, is built from non-pathogenic E. coli Nissle. It is designed to reach tumors and switch on the STING pathway, an alarm system inside immune cells.
Once swallowed up by antigen-presenting cells in the tumor, the bacteria trigger STING and other innate immune pathways together. In mouse tumor models, treatment produced strong anti-tumor immunity and lasting immunological memory. Human immune cells in the lab also responded robustly. Built-in containment features keep the strain from surviving where it should not. The authors present the work as a roadmap for designing living medicines that meet manufacturing and safety rules from the start.
Catalog record
| CREATOR | Leventhal DS, Sokolovska A, Li N, Plescia C, Kolodziej SA, Gallant CW, Christmas R, Gao JR, James MJ, Abin-Fuentes A, Momin M, Bergeron C, Fisher A, Miller PF, West KA, Lora JM. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 91 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |